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Standard two electrode voltage clamp techniques were used to investigate the response of neuronal nicotinic acetylcholine receptors, expressed in 
Xenopus oocytes, to various agonists and neuronal bungarotoxin (NBT). The p subunit is an important determinant of the receptor’s pharmaco- 
logical profile. Co-expression of aA and 82 subunits produced a receptor that was relatively insensitive to cytisine and nicotine and inhibited by 
NBT, whilst the a4@4 combination produced a receptor that was highly sensitive to cytisine and nicotine but resistant o toxin. The first 80 ammo 
acids of the N-terminal domain of the /I subunit are implicated in these characteristics, ince the combination of a4 with a hybrid /I subunit 
comprising amino acids 1 + 80 of/32 and 81 + 416 ofb4 became relatively insensitive to nicotine and cytisine and resistant o inhibition by neuronal 
buugarotoxin. 
Nicotinic receptor; Cbimeric subunit; Xenopus oocyte; Neuronal bungarotoxin 
1. INTRODUCTION 
The functional diversity of nicotinic acetylcholine re- 
ceptors (nAChRs) in the mammalian central nervous 
system is increased by the occurrence of multiple a and 
/I subunits which may be expressed in different pairwise 
combinations in distinct sets of neurons in particular 
regions of the brain [l] and at varying stages during 
development of the nervous system [2]. The differing 
pha~acolo~~ properties of these receptors have been 
examined by their expression in Xenon oocytes (re- 
viewed in [3]). Neuronal nAChRS are pentameric struc- 
tures, analogous to those found in muscle, and are com- 
prised of two a and three /3 subunits [4,5]. Both types 
of subunit contribute to the agonist binding [6], toxin 
sensitivity [7,8] and channel characteristics [9-l l] of the 
resulting receptor. For example, neuronal receptors 
containing a 82 type subunit are sensitive to inhibition 
by neuronal bungarotoxin INBT] and resistant to the 
actions of the nicotinic agonist cytisine, whilst a combi- 
nation of the same ct subunit with fl4 produces a recep- 
tor that is insensitive to NBT but striated by cytisine. 
Here we report the production of a @&?4 chimeric sub- 
unit consisting of the amino-terminal 80 residues of the 
82 subunit (approximately 38% of the extracellular do- 
main) joined to the appropriate remainder of the /34 
*Corresponding author. Fax: (44) (703) 594 319. 
**Present address; Department of Biochemistry, University of Bath, 
Bath, BA2 7AY, UK. 
sequence. The construct was co-expressed in oocytes 
with the neuronal a4 subunit and the pharmacological 
properties of the resulting receptor assessed in an effort 
to determine the relative contribution made by the 
amino-terminal region of the /I sequence. 
2. MATERIALS AND METHODS 
DNA and RNA modifying enzymes were supplied by Promega or 
Boehringer. All other reagents were from Sigma and were Analar 
grade or better. Neuronal b~~oto~n was supplied by Biotoxins 
Inc. General methods for restriction digests, fragment purification and 
ligation have been described elsewhere [l 11. The Bua(t chimeric sub- 
unit was constructed by cleavage of@4 cDNA in the vector pBluescript 
SK(-) (Stratagene Itd., Cambridge) with BumHI and Not1 to remove 
a 403 bp fragment which encoded the 5’ untranslated sequence, the 
signal peptide and residues 1 to 80 of the mature 84 protein. A PCR 
1121 method was used to introduce a BarnHI site in the analogous 
position in the /32 sequence (a single C to A change at nucleotide 244) 
and the corresponding 5’ fragment of the fl sequence was excised and 
puritied. This fragment was ligated into the BamHI/NotI cleaved 84 
containing vector. 
Messenger RNAs coding for the a3,82, /I4 and chimeric subunits 
were prepared by in vitro t~~ption of f~l-leng~ linear&l 
cDNAs as previously described 1131. Transcripts were stored as etha- 
nolic precipitates at -70°C. For injection transcripts were vortexed to 
produce a homogeneous mix, and a 5 fig aliquot of the required 
subunits removed, mixed and then centrifuged. Precipitates were 
washed in 70% (v/v) ethanol, dried then resuspended in ribonuclease 
free diethylpyrocarbonate reated water. Approximately 15 ng of each 
subunit was coinjected into individual oocytes in the required combi- 
nations in a total volume of 30 to 50 nl. 
Oocytes were removed from anaesthetised Xenopllr and treated with 
2 mg . ml-’ collagenase (Sigma type II) at 182O’C for 50 min followed 
by manual removal of the follicular layers using watchmakers forceps. 
Injected oocytes were maintained at = 18’C, for 2 to 5 days in changes 
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of SOS medium (100 mM NaCI, 2 mM KCl, 1.8 mM CaQ, 1 mM 
MgCI,, 5 mM HEPES, pH 7.6). For electrophysiological recording 
oocytes were held in a 1 ml perspex bath and impaled with two 
microelectrodes filled with 3 M KCl, pH 7.8. Both electrodes had 
resistances of less than 1 MQ. Oocytes were superfused with SOS 
plus 1 PM atropine at 12 ml * min-’ and clamped at -80 mV unless 
otherwise stated. The desired dose of agonist was added to perfusing 
SOS and applied for 5 s. To study the effect of NBT oocytes were 
incubated with the desired concentration of neurotoxin for 15 min 
prior to wash out and immediate application of agonist. Data acquisi- 
tion, storage and analysis were performed using a Dell System 200 PC 
AT using the programme pCLAMP. Peak current dose-response 
curves from 10-s M to lo-’ M were constructed for each agonist and 
data normalised to a non-desensitising dose in the mid range of the 
curve (10 ,uM) for each oocyte. 
3. RESULTS AND DISCUSSION 
Four ganglionic agonists, acetylcholine (ACh), 1 , 1 - 
dimethyl-4-phenylpiperazinium (DMPP), nicotine (Nit) 
and cytisine (Cyt) were applied to oocytes expressing 
/?2,84 or /?2/4 chimera in combination with cc4. In all 
cases oocytes expressing neuronal subunits exhibited 
dose dependent inward currents upon application of 
these agonists under voltage clamp. Fig. 1 shows the full 
dose-response curves for these agonists with the three 
receptor combinations under consideration. In order to 
examine the relative potency of these agonists, where 
absolute current values differed, a comparison was 
made with an equivalent dose (10 PM) of acetylcholine 
and these ratios are shown in Fig. 2. In common with 
others [6], we found that cytisine was the most potent 
agonist for a484 receptors ( x 5.68 an equivalent dose 
of ACh, n = 4) but a poor stimulant of a4/?2 ( x 0.29 the 
equivalent ACh dose, n = 4). Replacement of the first 
80 residues of the 84 polypeptide chain with the corre- 
sponding region of 82 resulted in a substantial decrease 
in the response to cytisine when applied to oocytes ex- 
pressing the chimeric subunit ( x 0.62 an equivalent 
ACh dose, n = 5). The conferment ofp2-like properties 
was also seen in the response to nicotine. The potency 
of nicotine as an agonist relative to ACh is similar for 
subunits containing/I2 or the chimera ( x 1 .O for 82 and 
x 1.13 for the chimera, n = 4 in both cases) when com- 
pared to 84 ( x 5.4, n = 3). The response of the chimera 
800 - 1500 
800 A - 
,250 
6 
700 - 
- 1000 
s 500 6 - 2 
750 _ i 
to the ganglionic agonist DMPP ( x 0.4 the ACh dose) 
was intermediate with those shown by a4/I4 ( x 0.13 the 
ACh dose) and a4B2 (x 0.68 the ACh dose) combina- 
tions. The potency of DMPP may reflect the relative 
contribution to agonist binding of more distal regions 
of the ,!I chain which have remained unchanged in the 
chimera, nevertheless the experiments presented here 
suggest hat regions within the first 80 residues of the 
/3 chain can exert a major influence on agonist sensitiv- 
ity. In a recent study Figl et al. [14] also demonstrated 
that a region towards the centre of the extracellular 
domain of the 84 subunit was a major determinant in 
conferring agonist sensitivity when B chimeras were co- 
expressed with a3. Their locahsation of this determinant 
to residues 105 to 115, rather than earlier in the se- 
quence, as our experiments indicate, may arise from 
differences in the nature of B chimeras or in the require- 
ments of the differing a subunits used for oocyte expres- 
sion. a3 and a4 expressed in oocytes with the same /I 
subunit show differing agonist sensitivities and rates of 
desensitisation [15]. Similar distinctions may also ex- 
tend to the nature and consequences of a/p interactions. 
A minor component of Bungarus multicinctus venom, 
known as neuronal bungarotoxin (NBT), blocks neu- 
ronal nicotinic receptors in the concentration range l@- 
100 nM but has relatively little effect, at similar concen- 
trations, on receptors found at the neuromuscular junc- 
tion [16-l 81. The sensitivity of neuronal receptors to 
NBT is another property which varies according to sub- 
unit composition and Fig. 3 shows the contribution of 
the /3 subunit towards susceptibility to toxin inhibition. 
Receptors composed of a4/?2/4 do not differ signifi- 
cantly from a4p2 in their response to 10 PM ace- 
tylcholine following treatment with 100 nM NBT, im- 
plying that at least some determinants for toxin binding 
reside in the amino-terminal region of the/Y polypeptide 
chain. 
Studies using a variety of crosslinking reagents [19] 
and synthetic peptides [20] have defined those regions 
of the a subunit which are involved in the binding of 
agonists and toxins to the extracellular domain of the 
assembled receptor. At present no such information is 
available for the p subunit, although expression of tran- 
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Fig. 1. Agonist-induced current responses for oocytes expressing the receptor subunit combinations aqB2 (A), o@4 (B) and ofI@/ (C). Currents 
were elicited by bath application of various concentrations of cytisine (k), DMPP (w), nicotine (0) and acetylcholine (0). 
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Fig. 2, Ratio of the cwrents induced by the application of IO FM of various agonists to that obtained fmm an identical dose of ~tyicho~e (the 
ratio for ACb is therefore 1). Each c&mm represents the mean 9 S.E.M. of the ratios of 3-5 separate oocytes from two different animals. The 
boxed portion of the figure shows typical responses of the three &imeric receptors to the application of IO PM cytisine; a = a4#2, b = a4#4* 
c = c&&!/4. The scale bars in the bottom left of the box represent 250 nA (vertical axis) and 5 s (horizontal axis). 
scripts in X&~opus oocytes [6,8] has indicated the modi- 
fying nature of this constituent on receptor pharmacol- 
ogy. One possibility is that the ligand binding site of 
neuronal nAGhRs is found at the interface of the a and 
/I chains and is comprised of parts of both subunits. 
Alternatively, the j3 subunit may act to modulate bind- 
ing by the cx subunit via allosteric interactions invoI~n~ 
regions of the po~~ptide chain or attached carbohy- 
drate groups. Here we show that, whatever the mecha- 
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Fig. 3. The action of 100 nM neuronal bungarotoxin (NBT) on 
oocytes expressing &%2 (n = 4), w%jC/4 (n = 10) and &4s4 (n = 3) 
receptors. Responses are presented after normalisation to the response 
of the same oocyte to 10 FM a~y~~o~ne (response to IO pM A# 
= la0) and are shown 2 S.E.M. 
nism involved, these characteristics of the /I subunit are 
determined by the first 80 residues of the polypeptide 
although we cannot identify as yet which determinants 
within this region are of primary importance. 
Putative asparagine-linked glycosylation sites in the 
extracellular domain are a common feature of all neu- 
ronal nicotinic genes sequenced thus far (for a review 
see [Zl]). Fig. 4 shows the glycosylation sites of the j32 
and 84 amino-terminal regions together with those pre- 
served in the 8214 construct. The binding of a large 
molecule such as a peptide toxin may be influenced by 
the cluster of branched oligosaccharide groups located 
between residues 72 and 145 in 84. Thus, the removal 
of one of these oligosaccharide groups by abolition of 
the attachment site at position 72 may serve to increase 
32 
15 72 117 145 
I34 
Fig. 4. Sites of oligos~ha~de attachment in the ~n~t~~~ ex- 
tracelIular domains of the j?2 and ft4 subunits and the chime&z &24 
construct. 
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the sensitivity of the chimera to inhibition by NBT. It 
is possible that the combined degree of glycosylation of 
both a andg subunits may contribute toward the differ- 
ing sensitivities to NBT shown by various subunit com- 
binations. For example, 62 in combination with a3 or 
a4 (both with two glycosylation sites) gives a receptor 
inhibited by pre-incubation with 100 nM NBT, in con- 
trast to a2#2 (a2 has three glycosylation sites) which is 
NBT-resistant at this concentration [8,21]. In combina- 
tion with the highly glycosylated 84 subunit however, 
both a3 and a4 are completely insensitive to NBT when 
pre-incubated with the toxin ([23] and this report). The 
influence of attached oligosaccharide groups may arise 
as a result of direct steric hindrance to the access of 
toxin or from a more subtle effect on the kinetics of 
toxin binding. In support of the latter proposal, Papke 
et al. [24] have recently shown that a384 receptors are 
inhibited by NBT if the toxin is co-applied with agonist 
rather than administered by pre-incubation. The infer- 
ence here is that subunit combination dictates the kinet- 
ics of toxin binding, and glycosylation may be one fac- 
tor in determining the relative association and dissocia- 
tion rates for this process. In agreement with our tind- 
ings, these authors also demonstrate a direct relation- 
ship between the origin of the amino terminal 130 resi- 
dues @2 or 84) and sensitivity to inhibition by neuro- 
toxin. 
The experiments reported here identify a region of the 
nicotinic neuronalp subunit which mediates two impor- 
tant functional properties of the receptor, response to 
different agonists and inhibition by neurotoxin. The 
significance. of post translational modifications and/or 
individual amino acids within this sequence can be es- 
tablished by oligonucleotide directed mutagenesis and 
is the subject of further investigation. 
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